Neu­rode­gen­er­a­tive biotech Vyant warns of po­ten­tial wind-down

The CEO and chief sci­en­tif­ic of­fi­cer of Vyant Bio are out the door as the lit­tle-known but pub­licly-list­ed neu­rode­gen­er­a­tive biotech search­es for an ex­it or, if all else fails, a wind-down.

The soul-search­ing book­ends a wind­ing jour­ney for the biotech, which re­brand­ed and tran­si­tioned from di­ag­nos­tics com­pa­ny Can­cer Ge­net­ics in 2021 af­ter a merg­er with Ste­moniX. That came af­ter a failed merg­er at­tempt with Nov­el­lus­Dx (now Fore Bio­ther­a­peu­tics) in 2018. In the last few years, units have been sold off and the stock price $VYNT has plum­met­ed from the $30 range to pen­ny stock ter­ri­to­ry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER